NEW BLOG 📖 Unpacking the FDA Advisory Committee Meeting for Merck's Gefapixant

M

Nick Delmonico, CEO of Strados Labs will be presenting on behalf of the company at ATA's Annual Conference on March 6th - where Strados will also be exhibiting.

Philadelphia, PA February 14, 2023 – Strados Labs today announced that it was named a finalist in the ATA Telehealth Innovators Challenge as part of the ‘Tools That Deliver Care’ category. Strados was recognized for its RESP Biosensor, a device used for remote monitoring that captures lung sounds and events like cough, wheezing and rhonchi, similar to a wearable stethoscope.

Twelve finalists were selected from a field of 40 companies that made it through the first round of judging, representing four key digital and telehealth solution categories. The 12 finalists will present their innovations in a live pitch competition on the main stage at ATA2023:

Femtech and Women’s Health
Nest Collaborative, Ouma Health, SimpliFed

In-patient Care Solutions
Oshi Health, Omnicure, Great Speech

The Patient Experience
Vori Health, Videra Health, Clearstep Health

Tools That Deliver Care
Strados Labs, Starling Medical, OPTAC-X Global SATCOM

“At Strados our goal is to improve access to diagnostic care for the thousands of people suffering from advanced pulmonary diseases such as COPD and Asthma,” said Strados CEO Nick Delmonico. “We are thrilled to be recognized by the American Telemedicine Association as part of this challenge along with other companies leading the way in telehealth.”

“When the ATA launched the first Telehealth Innovators Challenge last year, we did not anticipate the overwhelming response it would receive from leaders in virtual care at every level,” said Samir Batra, Founder and CEO, BAHA Enterprises, and Advisor and Emcee of the ATA Telehealth Innovators Challenge. “The Innovators Challenge has instantly become the premier platform to introduce the most exciting new innovations in virtual care and the companies selected to participate represent the best of the best in setting new standards in telehealth technology and service delivery. The live pitch competition will be an exciting opportunity for everyone who attends ATA2023 to get an insider’s view of the very latest advances that will shape the future of telehealth.”

A panel of industry leaders representing all areas of virtual care are serving as judges for the Innovators Challenge and will be selecting the final winners during the live pitch competition at ATA2023.

ATA2023 will be held March 4-6, 2023, at the Henry B. González Convention Center in San Antonio, Texas. In addition to the Telehealth Innovators Challenge, the meeting will include presentations and updates from hundreds of globally recognized leaders from every sector of virtual care. For more information or to register, please visit the ATA2023 website.

About Strados Labs

Strados Labs, a medical technology company harnessing the power of machine learning, is the developer of the RESP Biosensor: an FDA-cleared and CE marked wearable device that allows for remote monitoring of lung sounds such as cough, wheeze, rhonchi, and rales as well as other vitals and functions. The technology provides clinicians with remote insight into a patient’s worsening respiratory disease allowing for earlier intervention. The RESP biosensor is also used in clinical trials to support the development of new therapies. The company is based in Philadelphia and is privately owned.

Media Contact:
Gabe Steerman
215-906-5538
gabe@stradoslabs.com
www.stradoslabs.com